T45 Labs

What T45 Labs does

T45 Labs is a Silicon Valley-based medical device incubator and venture fund that builds and capitalizes cardiovascular medtech companies through a structured 'best-follower' strategy, entering indications after clinical need has been validated by incumbents and seeking to improve on existing concepts. The firm operates three portfolio companies targeting distinct cardiovascular disease segments: Advanced NanoTherapies (ANT), which has developed the SirPlux Duo dual-drug coated balloon holding FDA Breakthrough Device Designation for coronary in-stent restenosis and is expanding into below-the-knee (BTK) peripheral applications; VahatiCor, which is developing the A-FLUX Reducer for coronary microvascular dysfunction (CMD); and NuevoSono, an intravascular ultrasound (IVUS) imaging company with AI-enabled image interpretation under development.

The firm monetizes via a hybrid incubator/venture fund model. It manages two investment vehicles — T45 Fund-I, which closed at $25M oversubscribed in March 2025, and T45 Fund-II, which opened with a $50M target in 2026 — generating management fees on committed capital, while holding equity in portfolio companies with strategic acquisition as the primary exit path. Underlying IP is sourced from 25 patents (Marwan portfolio) and exclusive licenses to Cleveland Clinic-originated technologies, with first-in-human trials running across Australia, the Dominican Republic, New Zealand, and Spain to accelerate clinical advancement.

T45 Labs serves limited partners in its two funds and, implicitly, large cardiovascular medtech strategic acquirers (e.g., Edwards Lifesciences, Boston Scientific) as the targeted exit counterparties. The operating team draws from Cleveland Clinic Foundation, Boston Scientific, and Johnson & Johnson, with 450+ peer-reviewed publications, and has installed operators with prior exit track records — most notably Harry Rowland, former Endotronix CEO whose company was acquired by Edwards Lifesciences, now leading VahatiCor.

Name

T45 Labs

Legal name

T45 Labs LLC

Website

https://t45labs.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

T45 Labs is a Silicon Valley medtech incubator and venture fund that builds and funds cardiovascular device companies for strategic acquisition exits. It operates three portfolio companies developing drug-coated balloons, coronary microvascular dysfunction therapy, and intravascular ultrasound imaging systems.

Ownership category

akta.pro rank

Headquarters

HQ city

Santa Clara

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Fund Management Fees: T45 Labs manages venture funds (T45 Fund-I $25M closed, T45 Fund-II $50M open) and earns management fees on committed capital.
2. Carried Interest / Portfolio Company Exits: Returns generated through successful exit events (acquisition) of portfolio companies. T45 Labs positions companies for acquisition by strategic acquirers after building clinical proof.
3. Portfolio Company Equity: T45 Labs and T45 Fund hold equity positions in portfolio companies including Advanced NanoTherapies, VahatiCor, and NuevoSono.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

T45 Labs is a medical device incubator and venture fund that builds, funds, and advances minimally invasive cardiovascular technologies through portfolio companies. The company identifies clinically validated cardiovascular needs, licenses or develops proprietary device IP, and operates three portfolio companies: Advanced NanoTherapies (drug-coated balloon), VahatiCor (coronary sinus reducer), and NuevoSono (intravascular ultrasound). T45 Labs manages T45 Fund-I ($25M closed) and T45 Fund-II ($50M target), positions portfolio companies for strategic acquisition by large medtech firms after achieving clinical proof and regulatory milestones.

Differentiator

Problem solved

Functional benefit

Products and services

• T45 Fund-I Oversubscribed $25M venture fund financing cardiovascular medtech portfolio companies through early clinical development and toward strategic acquisition. Fully allocated across Advanced NanoTherapies, VahatiCor, and NuevoSono.
• T45 Fund-II $50M target venture fund as a direct continuation of Fund-I, focused on building the next wave of minimally invasive cardiovascular technologies and accelerating growth across the portfolio.
• SirPlux Duo Dual-Drug Drug-Coated Balloon Next-generation dual-drug (paclitaxel and sirolimus) nanoparticle-coated balloon for vascular intervention in coronary artery disease and below-the-knee peripheral applications. Uses functionalized nanoparticles to co-deliver two synergistic drugs simultaneously, enabling controlled, sustained drug delivery at the lesion site with higher potency at lower doses. Received FDA Breakthrough Device designation.
• A-FLUX Reducer System Coronary Sinus reducer implant using SwiftCell Technology—a small-cell proprietary design based on computational modeling—to redistribute oxygen supply to the sub-endocardium layer of the heart muscle. Features atraumatic expansion and repositionable design. Treats coronary microvascular dysfunction (CMD) and obstructive coronary artery disease with persistent symptoms.
• NuevoSono Wireless IVUS System Compact, plug-and-play intravascular ultrasound (IVUS) system with wireless design and no-footprint console, delivering high-definition imaging designed for daily clinical practice. Built with potential for AI-enabled image interpretation support (via SUPERWISE partnership for coronary lesion assessment).

Quantifiable outcome

• First-in-human trial of 28 patients showed no new treatment failures at two-year follow-up
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Cleveland CliniccoreTechnology or Integration · 2 June 2026Technology licensing partnership for nanoparticle drug delivery platform. SirPlux Duo technology exclusively licensed from Cleveland Clinic. Dr. Rishi Puri serves as Chief Medical Director at T45 Labs while working as interventional cardiologist at Cleveland Clinic.
• Samit Shah, MD PhD (Yale School of Medicine)coreOthersCo-principal investigator for VahatiCor SERRA-I early feasibility study. Leading coronary physiology expert focused on CMD treatment.
• Tim Van de Hoef, MD PhD (University Medical Center Utrecht)coreOthersCo-principal investigator for VahatiCor SERRA-I early feasibility study. European coronary physiology expert.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• InCube Labs: InCube Labs is a Silicon Valley–based medical device incubator founded by serial medtech entrepreneur Mir Imran. It is the closest direct peer to T45 Labs, running the same playbook of incubating multiple clinical-stage medical device companies for strategic acquisition, with a similarly focused cardiovascular and device orientation.
• Corvia Medical: Corvia Medical develops interventional devices for heart failure (interatrial shunt therapy), an adjacent structural cardiology product. Highly relevant peer given parallel regulatory pathway, similar clinical-trial-stage status, and overlap in interventional cardiology physician customers with T45 Labs' portfolio.
• Endotronix: Endotronix developed an implantable heart-failure sensor and was acquired by Edwards Lifesciences after FDA approval — led by current VahatiCor CEO Harry Rowland. A direct precedent for T45 Labs' playbook and a benchmark for the type of strategic-acquisition exit T45 Labs is targeting.
• Shifamed: Shifamed is a Silicon Valley medical device incubator that builds, funds, and operates multiple portfolio companies targeting structural heart, cardiology, and other specialty medtech markets. Operationally and structurally similar to T45 Labs as a multi-company incubator focused on strategic-exit outcomes.

Emerging players

• Adona Medical: Adona Medical is an emerging heart-failure device company spun out of Shifamed's incubator model. Comparable to T45 Labs' portfolio companies as a clinical-stage interventional cardiology play advancing through feasibility studies toward strategic exit.
• Orchestra BioMed: Orchestra BioMed is a clinical-stage biomedical company developing interventional cardiology therapies (notably drug-coated balloon and heart failure programs) often in partnership with strategic acquirers. Comparable to T45 Labs' portfolio on therapeutic focus (DCB, structural heart) and partnership-driven commercialization model.

Broad incumbents

• Longitude Capital: Longitude Capital is a well-established healthcare and medical device venture capital firm that invests across growth-stage medtech companies. A broad incumbent peer in cardiovascular device investing, with overlap in physician engagement and strategic-exit pathways but operating at a larger fund scale than T45 Labs.
• Boston Scientific: Boston Scientific is a major cardiovascular device company whose commercial leadership alumni (Sanj Kalra) are now at T45 Labs. Represents both a strategic-acquirer candidate for portfolio companies and an indirect capability benchmark for T45 Labs' commercialization-stage build-out.
• Edwards Lifesciences: Edwards Lifesciences is a large-cap structural heart and critical care medtech company and the most likely strategic acquirer profile for T45 Labs portfolio companies (acquired Endotronix). Relevant as the canonical strategic-exit counterparty in T45 Labs' business model.

Regional players

• S3 Ventures: S3 Ventures is a Texas-based early-stage venture firm that co-led Advanced NanoTherapies' $31M Series B. A relevant peer given co-investor status in T45 Labs' portfolio and similar preference for clinical-stage medical device rounds in the U.S. market.

Market position

Strengths2 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/t45-labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about T45 Labs